Welcome to our dedicated page for Clearmind Medici news (Ticker: CMND), a resource for investors and traders seeking the latest updates and insights on Clearmind Medici stock.
Clearmind Medicine Inc. (CMND) is a clinical-stage biotech company advancing novel psychedelic-derived therapies for mental health and addiction disorders. This page provides investors and stakeholders with timely updates on the company’s progress in developing non-hallucinogenic treatments, including its MEAI-based therapeutic pipeline.
Access the latest press releases, clinical trial developments, and strategic partnership announcements. Stay informed about Clearmind’s expanding intellectual property portfolio, regulatory milestones, and research collaborations with leading institutions. Content spans preclinical updates, patent grants, and progress toward addressing conditions like alcohol use disorder (AUD) and binge behaviors.
Bookmark this page for direct access to verified CMND news, ensuring you stay current on advancements in psychedelic therapeutics. Check regularly for updates on the company’s mission to deliver safe, accessible treatments through rigorous clinical research and innovative science.
Clearmind Medicine (Nasdaq: CMND) has signed a non-binding Letter of Intent with Polyrizon (Nasdaq: PLRZ) to develop a novel intranasal formulation for its psychedelic-based treatments. The collaboration aims to enhance the delivery of Clearmind's proprietary drug candidate, 5-Methoxy-2-aminoindane (MEAI), alone or combined with Palmitoylethanolamide (PEA).
The partnership focuses on developing an intranasal delivery system that could offer several advantages including:
- Faster absorption and onset of action
- Higher bioavailability for increased therapeutic effects
- Enhanced patient compliance through non-invasive administration
Under the agreement, Clearmind will fund the R&D process, while Polyrizon will advance formulation development using its proprietary intranasal drug delivery platform. Upon successful proof of concept, the parties plan to negotiate a definitive agreement covering IP rights, commercialization, and financial terms.
Clearmind Medicine (Nasdaq: CMND) has initiated its Phase I/IIa clinical trial for CMND-100, marking its transition to a clinical-stage pharmaceutical company. The trial will evaluate the safety, tolerability, and pharmacokinetics of CMND-100 in Alcohol Use Disorder (AUD) patients.
The study will be conducted at three prestigious institutions: IMCA in Israel, led by Prof. Mark Weiser, Yale School of Medicine's Department of Psychiatry, and Johns Hopkins University School of Medicine. The trial will also assess preliminary efficacy in reducing alcohol cravings and consumption.
CMND-100 is the company's proprietary MEAI-based oral drug candidate, designed to offer a novel approach by modulating reward mechanisms associated with addictive behavior. This represents a potential breakthrough in addressing the global AUD crisis, which affects approximately 400 million people worldwide and contributes to 2.6 million deaths annually according to WHO data.
Clearmind Medicine (NASDAQ: CMND) has secured a patent publication in South Korea for its innovative combination therapy using MEAI and N-Acylethanolamines to treat cocaine addiction. The patent is based on successful preclinical trials conducted at Bar-Ilan University's Gonda Multidisciplinary Brain Research Center in Israel.
The research demonstrated that animals treated with MEAI showed significant reduction in cocaine-induced cravings while maintaining normal responses to natural rewards like sucrose. This suggests MEAI specifically targets drug-related compulsions without affecting the general reward system.
The development is part of Clearmind's collaboration with SciSparc (NASDAQ: SPRC), combining Clearmind's MEAI psychedelic treatment with SciSparc's PEA for addiction and mental health applications. Multiple patent applications have been filed in the U.S. and other global jurisdictions.
Clearmind Medicine (Nasdaq: CMND) has announced the publication of a patent by Mexico's National Patent Office (IMPI) for its combination therapy treatment. The patent covers an innovative treatment combining MEAI and N-Acylethanolamines, targeting various binge behaviors including alcohol, eating, tobacco, shopping, and sexual conduct.
The patent emerged from Clearmind's collaboration with SciSparc (Nasdaq: SPRC), focusing on developing treatments for central nervous system disorders. The partnership aims to research combination therapies that integrate psychedelic compounds with N-Acylethanolamines family, including Palmitoylethanolamide (PEA).
Clearmind Medicine (Nasdaq: CMND), a clinical-stage biotech company developing psychedelic-derived therapeutics, announced the successful approval of all matters presented at its January 6, 2025 shareholders meeting. Key approvals include:
- Setting the board of directors at five members
- Election of directors for the upcoming year
- Appointment of Brightman Almagor Zohar & Co. (Deloitte Global Network) as company auditor
- Establishment of an omnibus equity incentive plan
- Authorization for potential share consolidation up to 50:1 ratio at board's discretion
Clearmind Medicine (Nasdaq: CMND) announced the publication of a European patent application for its combination therapy using MEAI and N-Acylethanolamines. The therapy targets various binge behaviors, including alcohol, eating, tobacco, shopping, and sexual conduct.
The patent stems from Clearmind's collaboration with SciSparc (Nasdaq: SPRC), focusing on combining psychedelic compounds with N-Acylethanolamines family, including Palmitoylethanolamide (PEA). The company has filed 13 patents across multiple jurisdictions related to this collaboration, strengthening its intellectual property portfolio in psychedelic therapies for binge behavior treatment.
Clearmind Medicine (NASDAQ: CMND) has received patent approval from the Macau International Intellectual Property Office for its MEAI-based binge behavior regulator program. The patent covers primary amine aminoindan compounds, including but not to 5-methoxy-2-aminoindan (MEAI), for regulating binge behavior.
This addition to Clearmind's intellectual property portfolio brings their total to 31 granted patents across 18 patent families, with coverage in major jurisdictions including the US, Europe, China, India, Hong Kong, and Macau. The company focuses on developing non-hallucinogenic proprietary molecules for treating substance addictions related to alcohol and food.
Clearmind Medicine (NASDAQ: CMND) has signed a non-binding term sheet with Dr Glitter Pty to develop and commercialize a novel MEAI-based alcohol substitute using Dr Glitter's ActivCrystal™ technology. The collaboration aims to create a product that replicates alcohol's sensations without health risks or hangovers.
The ActivCrystal™ format consists of tasteless, odorless crystals made from natural ingredients that can be sprinkled on meals. Users will be able to adjust dosage individually by sprinkling the MEAI-based alternative into beverages or food. This partnership represents a strategic move in Clearmind's efforts to bring MEAI to global markets as a solution to combat alcohol misuse.
Clearmind Medicine (NASDAQ: CMND) has received Institutional Review Board (IRB) approval for its Phase I/IIa clinical trial of CMND-100, targeting alcohol use disorder (AUD). The trial will be conducted at Yale School of Medicine's Department of Psychiatry under Dr. Anahita Bassir Nia's leadership. This FDA-regulated clinical program aims to evaluate the safety, tolerability, and efficacy of CMND-100 in reducing alcohol cravings and consumption among individuals with moderate to severe AUD.
The development addresses a significant global health issue, as alcohol consumption causes 2.6 million deaths annually worldwide and represents 4.7% of global deaths. Current AUD treatments face challenges including high costs, low efficacy (less than 30%), and poor patient compliance due to side effects.
Clearmind Medicine (NASDAQ: CMND) has signed a non-binding term sheet with Dr. Glitter Pty to develop and commercialize a novel MEAI-based alcohol substitute using ActivCrystal™ technology. The collaboration aims to create a product that replicates alcohol's sensations without health risks or hangovers.
The ActivCrystal™ technology encapsulates active ingredients in tasteless, odorless crystals made from natural ingredients that can be sprinkled on meals. Upon finalizing a definitive agreement, the product will allow users to add MEAI-based crystals to their choice of beverage or food with adjustable dosage.
This partnership represents a strategic move in Clearmind's efforts to introduce MEAI to global markets as a solution to combat alcohol misuse.
FAQ
What is the current stock price of Clearmind Medici (CMND)?
What is the market cap of Clearmind Medici (CMND)?
